请输入您要查询的百科知识：

　

词条 Myeloperoxidase
释义

  1. Structure

  2. Function

  3. Clinical significance

      Medical uses    Inhibitors of MPO  

  4. See also

  5. References

{{infobox enzyme
| Name = Myeloperoxidase
| EC_number = 1.11.2.2
| CAS_number =
| IUBMB_EC_number = 1/11/2/2
| GO_code =
| image =
| width =
| caption =
}}{{Infobox_gene}}

Myeloperoxidase (MPO) is a peroxidase enzyme that in humans is encoded by the MPO gene on chromosome 17.[1] MPO is most abundantly expressed in neutrophil granulocytes (a subtype of white blood cells), and produces hypohalous acids to carry out their antimicrobial activity.[1][2] It is a lysosomal protein stored in azurophilic granules of the neutrophil and released into the extracellular space during degranulation.[3] Neutrophil myeloperoxidase has a heme pigment, which causes its green color in secretions rich in neutrophils, such as pus and some forms of mucus. The green color contributed to its outdated name verdoperoxidase.

Structure

The 150-kDa MPO protein is a cationic homodimer consisting of two 15-kDa light chains and two variable-weight glycosylated heavy chains bound to a prosthetic heme group.[4][5][6] The light chains are glycosylated and contain the modified iron protoporphyrin IX active site. Together, the light and heavy chains form two identical 73-kDa monomers connected by a cystine bridge at Cys153. The protein forms a deep crevice which holds the heme group at the bottom, as well as a hydrophobic pocket at the entrance to the distal heme cavity which carries out its catalytic activity.[6]

Three isoforms have been identified, differing only in the size of the heavy chains.[4]

MPO contains a calcium binding site with seven ligands, forming a pentagonal pyramid conformation.{{citation needed|date=August 2015}} One of the ligands is the carbonyl group of Asp 96. Calcium-binding is important for structure of the active site because of Asp 96's close proximity to the catalytic His95 side chain.[7]

Function

MPO is a member of the XPO subfamily of peroxidases and produces hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and chloride anion (Cl−) (or the equivalent from a non-chlorine halide) during the neutrophil's respiratory burst. It requires heme as a cofactor. Furthermore, it oxidizes tyrosine to tyrosyl radical using hydrogen peroxide as an oxidizing agent.[4][8] Hypochlorous acid and tyrosyl radical are cytotoxic, so they are used by the neutrophil to kill bacteria and other pathogens.[9] However, this hypochlorous acid may also cause oxidative damage in host tissue. Moreover, MPO oxidation of apoA-I reduces HDL-mediated inhibition of apoptosis and inflammation.[10] In addition, MPO mediates protein nitrosylation and the formation of 3-chlorotyrosine and dityrosine crosslinks.[4]

Clinical significance

Myeloperoxidase deficiency is a hereditary deficiency of the enzyme, which predisposes to immune deficiency.[11]Antibodies against MPO have been implicated in various types of vasculitis, most prominently three clinically and pathologically recognized forms: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA); and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). Antibodies are also known as anti-neutrophil cytoplasmic antibodies (ANCAs), though ANCAs have also been detected in staining of the perinuclear region.[12]

Recent studies have reported an association between elevated myeloperoxidase levels and the severity of coronary artery disease.[13] And Heslop et al. reported that elevated MPO levels more than doubled the risk for cardiovascular mortality over a 13-year period.[14] It has also been suggested that myeloperoxidase plays a significant role in the development of the atherosclerotic lesion and rendering plaques unstable.[15][16]

Medical uses

An initial 2003 study suggested that MPO could serve as a sensitive predictor for myocardial infarction in patients presenting with chest pain.[17] Since then, there have been over 100 published studies documenting the utility of MPO testing. The 2010 Heslop et al. study reported that measuring both MPO and CRP (C-reactive protein; a general and cardiac-related marker of inflammation) provided added benefit for risk prediction than just measuring CRP alone.[14]

Immunohistochemical staining for myeloperoxidase used to be administered in the diagnosis of acute myeloid leukemia to demonstrate that the leukemic cells were derived from the myeloid lineage. Myeloperoxidase staining is still important in the diagnosis of myeloid sarcoma, contrasting with the negative staining of lymphomas, which can otherwise have a similar appearance.[18] In the case of screening patients for vasculitis, flow cytometric assays have demonstrated comparable sensitivity to immunofluorescence tests, with the additional benefit of simultaneous detection of multiple autoantibodies relevant to vasculitis. Nonetheless, this method still requires further testing.[19]

Myeloperoxidase is the first and so far only human enzyme known to break down carbon nanotubes, allaying a concern among clinicians that using nanotubes for targeted delivery of medicines would lead to an unhealthy buildup of nanotubes in tissues.[20]

Inhibitors of MPO

Azide has been used traditionally as an MPO inhibitor, but 4-aminobenzoic acid hydrazide (4-ABH) is a more specific inhibitor of MPO.[21]

See also

  • Chloroma

References

1. ^1 {{cite web | title = Entrez Gene: Myeloperoxidase | url = https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=retrieve&list_uids=4353 }}
2. ^{{cite journal | vauthors = Klebanoff SJ | title = Myeloperoxidase: friend and foe | journal = Journal of Leukocyte Biology | volume = 77 | issue = 5 | pages = 598–625 | date = May 2005 | pmid = 15689384 | doi = 10.1189/jlb.1204697 }}
3. ^{{cite journal | vauthors = Kinkade JM, Pember SO, Barnes KC, Shapira R, Spitznagel JK, Martin LE | title = Differential distribution of distinct forms of myeloperoxidase in different azurophilic granule subpopulations from human neutrophils | journal = Biochemical and Biophysical Research Communications | volume = 114 | issue = 1 | pages = 296–303 | date = Jul 1983 | pmid = 6192815 | doi=10.1016/0006-291x(83)91627-3}}
4. ^1 2 3 {{cite web|url=http://bioaimscientific.com/sites/default/files/manual/MouseMPOELISA.pdf|title=Mouse MPO EasyTestTM ELISA Kit}}
5. ^{{cite journal | vauthors = Mathy-Hartert M, Bourgeois E, Grülke S, Deby-Dupont G, Caudron I, Deby C, Lamy M, Serteyn D | title = Purification of myeloperoxidase from equine polymorphonuclear leucocytes | journal = Canadian Journal of Veterinary Research | volume = 62 | issue = 2 | pages = 127–32 | date = Apr 1998 | pmid = 9553712 | pmc = 1189459 | doi = }}
6. ^1 {{cite journal | vauthors = Davies MJ | title = Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention | journal = Journal of Clinical Biochemistry and Nutrition | volume = 48 | issue = 1 | pages = 8–19 | date = Jan 2011 | pmid = 21297906 | doi = 10.3164/jcbn.11-006FR | pmc=3022070}}
7. ^{{cite journal | vauthors = Shin K, Hayasawa H, Lönnerdal B | title = Mutations affecting the calcium-binding site of myeloperoxidase and lactoperoxidase | journal = Biochemical and Biophysical Research Communications | volume = 281 | issue = 4 | pages = 1024–9 | date = Mar 2001 | pmid = 11237766 | doi = 10.1006/bbrc.2001.4448 }}
8. ^{{cite journal | vauthors = Heinecke JW, Li W, Francis GA, Goldstein JA | title = Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins | journal = The Journal of Clinical Investigation | volume = 91 | issue = 6 | pages = 2866–72 | date = Jun 1993 | pmid = 8390491 | pmc = 443356 | doi = 10.1172/JCI116531 }}
9. ^{{cite journal | vauthors = Hampton MB, Kettle AJ, Winterbourn CC | title = Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing | journal = Blood | volume = 92 | issue = 9 | pages = 3007–17 | date = Nov 1998 | pmid = 9787133 }}
10. ^{{vcite2 journal | vauthors = Shao B, Oda MN, Oram JF, Heinecke JW | title = Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein | journal = Chemical Research in Toxicology | volume = 23 | issue = 3 | pages = 447–54 | date = Mar 2010 | pmid = 20043647 | doi = 10.1021/tx9003775 | pmc=2838938}}
11. ^{{cite journal | vauthors = Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A | title = Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ? | journal = Acta Haematologica | volume = 104 | issue = 1 | pages = 10–5 | year = 2000 | pmid = 11111115 | doi = 10.1159/000041062 }}
12. ^{{cite journal | vauthors = Flint SM, McKinney EF, Smith KG | title = Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis | journal = Current Opinion in Rheumatology | volume = 27 | issue = 2 | pages = 197–203 | date = Mar 2015 | pmid = 25629443 | doi = 10.1097/BOR.0000000000000145 }}
13. ^{{cite journal | vauthors = Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL | title = Association between myeloperoxidase levels and risk of coronary artery disease | journal = JAMA | volume = 286 | issue = 17 | pages = 2136–42 | date = Nov 2001 | pmid = 11694155 | doi = 10.1001/jama.286.17.2136 }}
14. ^1 {{cite journal | vauthors = Heslop CL, Frohlich JJ, Hill JS | title = Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography | journal = Journal of the American College of Cardiology | volume = 55 | issue = 11 | pages = 1102–9 | date = Mar 2010 | pmid = 20223364 | doi = 10.1016/j.jacc.2009.11.050 }}
15. ^{{cite journal | vauthors = Nicholls SJ, Hazen SL | title = Myeloperoxidase and cardiovascular disease | journal = Arteriosclerosis, Thrombosis, and Vascular Biology | volume = 25 | issue = 6 | pages = 1102–11 | date = Jun 2005 | pmid = 15790935 | doi = 10.1161/01.ATV.0000163262.83456.6d }}
16. ^{{cite journal | vauthors = Lau D, Baldus S | title = Myeloperoxidase and its contributory role in inflammatory vascular disease | journal = Pharmacology & Therapeutics | volume = 111 | issue = 1 | pages = 16–26 | date = Jul 2006 | pmid = 16476484 | doi = 10.1016/j.pharmthera.2005.06.023 }}
17. ^{{cite journal | vauthors = Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL | title = Prognostic value of myeloperoxidase in patients with chest pain | journal = The New England Journal of Medicine | volume = 349 | issue = 17 | pages = 1595–604 | date = Oct 2003 | pmid = 14573731 | doi = 10.1056/NEJMoa035003 }}
18. ^{{cite book | author = Leong A S-Y, Cooper K, Leong, FJ W-M | title = Manual of Diagnostic Antibodies for Immunohistology | publisher = Greenwich Medical Media | location = London | year = 2003 | pages = 325–326 | isbn = 1-84110-100-1 }}
19. ^{{cite journal | vauthors = Csernok E, Moosig F | title = Current and emerging techniques for ANCA detection in vasculitis | journal = Nature Reviews. Rheumatology | volume = 10 | issue = 8 | pages = 494–501 | date = Aug 2014 | pmid = 24890776 | doi = 10.1038/nrrheum.2014.78 }}
20. ^{{cite journal | vauthors = Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, Vlasova II, Belikova NA, Yanamala N, Kapralov A, Tyurina YY, Shi J, Kisin ER, Murray AR, Franks J, Stolz D, Gou P, Klein-Seetharaman J, Fadeel B, Star A, Shvedova AA | title = Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation | journal = Nature Nanotechnology | volume = 5 | issue = 5 | pages = 354–9 | date = May 2010 | pmid = 20364135 | doi = 10.1038/nnano.2010.44 | laysummary = http://www.popsci.com/science/article/2010-04/enzyme-blood-cells-breaks-down-carbon-nanotubes-paving-way-nano-delivered-drugs | laysource = popsci.com }}
21. ^{{cite journal | vauthors = Kettle AJ, Gedye CA, Winterbourn CC | title = Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide | journal = The Biochemical Journal | volume = 321 | issue = 2| pages = 503–8 | date = Jan 1997 | pmid = 9020887 | pmc = 1218097 | doi = 10.1042/bj3210503| series = 321 }}
{{PDB_Gallery|geneid=4353}}{{Granule contents}}{{Peroxidases}}{{Enzymes}}{{Portal bar|Molecular and Cellular Biology|border=no}}

2 : EC 1.11.1|Hemoproteins
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/27 5:52:33